{"id":{"repo_id":"umn","oai_identifier":"oai:conservancy.umn.edu:11299/160069"},"canonical_url":"https://search.dev.ndltd.org/etd/umn/oai:conservancy.umn.edu:11299/160069","repository":{"repo_id":"umn","name":"University of Minnesota","base_url":"https://conservancy.umn.edu/server/oai/request"},"display":{"title":"Development and characterization of novel toxoplasma gondii inhibitors","abstract":"Toxoplasma gondii</italic> is an obligate intracellular, protozoan parasite of the phylum Apicomplexa. While the parasite relies on the feline to complete its life-cycle, many mammals can contract the infection. In humans, infection can cause serious illness or death. Treatments currently available are limited by toxicity and teratogenicity. This necessitates the development of novel drug compounds. Tryptanthrin and its analogue, 8-bromotryptanthrin, have shown promise in the treatment of <italic>Toxoplasma gondii in vitro</italic>. New tryptanthrin derivatives were synthesized, characterized, and tested for efficacy and toxicity. These compounds show a structure-activity relationship at the 8-position and low toxicity.","abstract_html":"Toxoplasma gondii&lt;/italic&gt; is an obligate intracellular, protozoan parasite of the phylum Apicomplexa. While the parasite relies on the feline to complete its life-cycle, many mammals can contract the infection. In humans, infection can cause serious illness or death. Treatments currently available are limited by toxicity and teratogenicity. This necessitates the development of novel drug compounds. Tryptanthrin and its analogue, 8-bromotryptanthrin, have shown promise in the treatment of &lt;italic&gt;Toxoplasma gondii in vitro&lt;/italic&gt;. New tryptanthrin derivatives were synthesized, characterized, and tested for efficacy and toxicity. These compounds show a structure-activity relationship at the 8-position and low toxicity.","abstract_has_math":false,"creators":["Czerniecki, Nikolas Johann"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-04","date_published":"2013-04","updated_at":"2026-07-24T05:19:52Z","subjects":[],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://purl.umn.edu/160069","outbound_label":"Repository record","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Czerniecki, Nikolas Johann"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2013-11-11T17:53:43Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2013-11-11T17:53:43Z"]},{"key":"dc:date.issued","label":"Date","values":["2013-04"]},{"key":"dc:type","label":"Dc Type","values":["Thesis or Dissertation"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://purl.umn.edu/160069"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["University of Minnesota M.S. thesis. April 2013. Major: Chemistry. Advisor: Peter Grundt. 1 computer file (PDF); vi, 133 pages, appendix I."]},{"key":"dc:description.abstract","label":"Abstract","values":["Toxoplasma gondii</italic> is an obligate intracellular, protozoan parasite of the phylum Apicomplexa. While the parasite relies on the feline to complete its life-cycle, many mammals can contract the infection. In humans, infection can cause serious illness or death. Treatments currently available are limited by toxicity and teratogenicity. This necessitates the development of novel drug compounds. Tryptanthrin and its analogue, 8-bromotryptanthrin, have shown promise in the treatment of <italic>Toxoplasma gondii in vitro</italic>. New tryptanthrin derivatives were synthesized, characterized, and tested for efficacy and toxicity. These compounds show a structure-activity relationship at the 8-position and low toxicity."]},{"key":"dc:title","label":"Title","values":["Development and characterization of novel toxoplasma gondii inhibitors"]}]}],"canonical_facts":{"dc:creator":["Czerniecki, Nikolas Johann"],"dc:date.accessioned":["2013-11-11T17:53:43Z"],"dc:date.available":["2013-11-11T17:53:43Z"],"dc:date.issued":["2013-04"],"dc:description":["University of Minnesota M.S. thesis. April 2013. Major: Chemistry. Advisor: Peter Grundt. 1 computer file (PDF); vi, 133 pages, appendix I."],"dc:description.abstract":["Toxoplasma gondii</italic> is an obligate intracellular, protozoan parasite of the phylum Apicomplexa. While the parasite relies on the feline to complete its life-cycle, many mammals can contract the infection. In humans, infection can cause serious illness or death. Treatments currently available are limited by toxicity and teratogenicity. This necessitates the development of novel drug compounds. Tryptanthrin and its analogue, 8-bromotryptanthrin, have shown promise in the treatment of <italic>Toxoplasma gondii in vitro</italic>. New tryptanthrin derivatives were synthesized, characterized, and tested for efficacy and toxicity. These compounds show a structure-activity relationship at the 8-position and low toxicity."],"dc:identifier.uri":["http://purl.umn.edu/160069"],"dc:language.iso":["en_US"],"dc:title":["Development and characterization of novel toxoplasma gondii inhibitors"],"dc:type":["Thesis or Dissertation"]},"updated_at":"2026-07-24T05:19:52Z"}